Thursday, Oct 29 2020 | Time 17:08 Hrs(IST)
  • Mayawati vows to defeat SP, supports BJP
  • BJP has no criminal background candidate in UP bypolls: ADR report
  • 609 Air Warriors inducted into IAF
  • PM Imran acquitted in Parliament house attack case
  • Haryana govt issues directions to initiate recoveries in 3 graft cases
  • Cabinet approves MoU b/w India & Cambodia on cooperation in Health & Medicine
  • PMLA case : Principal Sessions Court sends Sivasankar to seven day ED custody
  • Cabinet approves Externally Aided Dam Rehabilitation & Improvement Project – Ph II and Ph III
  • Centre has no love for people of J&K, only wants its resources and land : Mehbooba
  • Sensex drops 172 61 pts
  • Cabinet approves extension of norms for mandatory packaging in jute bags
  • Suriya, Ruhaan & Ishaan poised to clinch National Karting C'ship titles
  • ED arrests Bineesh Kodiyeri in drug bust case in Bengaluru
  • L&T down by 4 99 pc to Rs 934 60
  • Soumitra Chatterjee still on ventilator support but first session of his dialysis goes well
Business Economy

Direct Biologics Initiates Patient Enrollment in the Phase II EXIT COVID-19 Clinical Trial

AUSTIN, Texas, Sept. 9, 2020 /PRNewswire/ -- Direct Biologics, LLC announced the launch today of EXIT COVID-19, their Phase II, multi-center clinical trial examining the use of ExoFlo™ extracellular vesicles to treat COVID-19 associated acute respiratory distress syndrome (ARDS). Preclinical studies of these extracellular vesicles secreted by bone marrow-derived mesenchymal stem cells (bmMSCs) suggest that they may have the ability to downregulate inflammation and upregulate tissue repair in humans.
EXIT COVID-19 has initiated enrollment of 75 COVID-19 patients with moderate-to-severe ARDS at multiple research sites across the U.S. The primary efficacy endpoints will be all-cause mortality and median days to recovery.
Chief Medical Officer Vik Sengupta, MD, states, "We have pursued a relentless path since April 2020 when the 24 inpatients were treated, and ExoFlo's potential as a therapeutic countermeasure against severe COVID-19 first became clear. Patients in the U.S. deserve safe, innovative therapies that meet the highest standards of value and evidence-based medicine, and our phase II double-blind, placebo-controlled, randomized clinical trial is the next step in that process. It will continue to be my priority to maintain these standards as we investigate the potential benefit of ExoFlo as a treatment for COVID-19 associated ARDS."
More News

Hikvision reports Q3 2020 financial results

29 Oct 2020 | 5:06 PM

HANGZHOU, China, Oct. 29, 2020 /PRNewswire/ -- Hikvision, an IoT solution provider with video as its core competency, has reported its financial results for the third quarter of 2020. During the quarter, Hikvision generated a revenue of RMB 17.75 billion with a year-over-year (YoY) increase of 11.53%, and net profits attributable to shareholders of the company was RMB 3.81 billion, reflecting a YoY growth of 0.12%.

see more..

Acko General Insurance partners with Kapture CRM to optimize its customer support

29 Oct 2020 | 4:44 PM

Bengaluru, Oct 29 (UNI) Kapture CRM, an enterprise-grade cloud-based SaaS Customer Relationship Management company, has on-boarded Acko General Insurance, an insurtech company in India. Acko Insurance will leverage Kapture’s advanced CRM capabilities to streamline its customer support processes.

see more..
Sensex drops 172 61 pts

Sensex drops 172 61 pts

29 Oct 2020 | 4:41 PM

Mumbai, Oct 29 (UNI) Extending losses for another day on Thursday the Sensex dropped by 172.61 pts to settle at 39,749.85 on heavy selling in Capital Goods, Consumer Durable, Utilities, Industrials and FMCG stocks amid weak Asian Market.

see more..

Beginners in CFD Trading Should Learn These Tricks To Get Success

29 Oct 2020 | 4:27 PM

Oct 29, 2020 (UNI/Media officer): The people aiming to take a plunge in CFD Trading strategies require to know trick of the trade to gain success in it. The beginners should move in this business step-by-step.

see more..

L&T down by 4 99 pc to Rs 934 60

29 Oct 2020 | 4:16 PM

Mumbai, Oct 29 (UNI) L&T on Thursday slipped by 4.99 per cent to Rs 934.60, a major loser in 30 scrips of BSE.

see more..